Adverse events leading to change or discontinuation of itraconazole therapy for both Group A and B patients.

<p>Adverse events leading to change or discontinuation of itraconazole therapy for both Group A and B patients.</p

Weight, <i>Aspergillus</i> IgG, quality of life score, and MRC dyspnoea scores for patients not on any therapy at 12 months evaluated at baseline, 6 and 12 months.

<p>N = 56.</p

Change in St. George’s quality of life score at baseline, 6 months and 12 months for patients who were only on voriconazole (A) and itraconazole (B) for 12 months and for patients in whom voriconazole (C) or itraconazole (D) was discontinued.

<p><b>Key</b>: <b>+</b>, mean score: <b>Middle bar</b>, Median.</p

Variations in the <i>Aspergillus</i>-specific IgG at baseline, 6 months and 12 months for patients who were only on voriconazole (A) or itraconazole (B) for 12 months and for patients in whom voriconazole (C) or itraconazole (D) was discontinued.

<p><b>Key</b>: <b>+</b>, mean score.: <b>Middle bar</b>, Median.</p

Weight, <i>Aspergillus</i> IgG, quality of life score, and MRC dyspnoea scores for all patients evaluated at baseline, 6 and 12 months.

<p>N = 206.</p

Patients selection, stratification and treatment course for all the patients referred to the National Aspergillosis Centre over 24 months.

<p>Abbreviation: <b>NAC</b>. National Aspergillosis Centre.</p

Adverse events leading to change or discontinuation of voriconazole therapy for both Group A and B patients.

<p>Adverse events leading to change or discontinuation of voriconazole therapy for both Group A and B patients.</p

Kaplan-Meier survival plots for chronic pulmonary aspergillosis patients who were commenced on itraconazole and voriconazole as primary therapy (4A) and for Group A and B patients (4B).

<p>There was no statistical difference in mortality across primary therapy antifungal agents (log-rank, p = 0.462) and across the 2 groups (log-rank, p = 0.173).</p

Weight, <i>Aspergillus</i> IgG, quality of life score, and MRC dyspnoea scores for patients on any oral therapy at 12 months evaluated at baseline, 6 and 12 months.

<p>N = 140.</p

Underlying and co-existing pulmonary disorders among patients with chronic pulmonary aspergillosis.

<p>Underlying and co-existing pulmonary disorders among patients with chronic pulmonary aspergillosis.</p